溢价高达60%!艾伯维拟109亿美元收购Apogee,最快今日官宣

智通财经
Jun 22

智通财经APP获悉,据知情人士透露,艾伯维(ABBV.US)正接近达成一项斥资近 110 亿美元收购抗炎药物研发商 Apogee Therapeutics(APGE.US)的协议。这笔交易预计将成为这家制药巨头自 2019 年以来规模最大的补强式收购。

知情人士称,根据正在讨论的收购条款,Apogee的投资者将获得 109 亿美元的现金,这意味着较该公司最近的收盘价有约 60% 的溢价。

在没有最后时刻变动的前提下,该交易预计最早将于周一宣布。

Apogee的股价在过去 12 个月里上涨了一倍多,其中在 3 月份其核心候选药物 zumilokibart 针对特应性皮炎(一种炎症性皮肤病)的中期试验取得积极结果后,股价上涨了近 20%。

一笔潜在的交易将进一步增强艾伯维的免疫学产品线。该产品线由其抗炎药物修美乐(Humira)、喜达诺(Skyrizi)和林沃克(Rinvoq)领衔,这些药物去年总计创造了 304 亿美元的收入,同比增幅约为 14%。

如果最终敲定,该交易预计将成为这家总部位于芝加哥的制药巨头自 2019 年斥资 800 亿美元收购保妥适(Botox)制造商艾尔建以来规模最大的一笔交易。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10